Search

Search Constraints

You searched for: Author/Creator Kumada, Takashi

Search Results

1. A 48‐week telaprevir‐based triple combination therapy improves sustained virological response rate in previous non‐responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study. Issue 14 (15th April 2014)

2. A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin–bilirubin grade. Issue 3 (2nd August 2017)

3. Abnormal fucosylation of alpha‐fetoprotein in patients with nonalcoholic steatohepatitis. Issue 5 (19th March 2021)

6. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. (22nd July 2021)

7. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. (14th December 2022)

8. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. Issue 2 (5th January 2021)

9. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Issue 5 (9th February 2022)

10. Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness. Issue 1 (January 2015)